EPIC-HR
Nirmatrelvir-Ritonavir in High-Risk Outpatients with COVID-19
Patient / Population Intervention / Exposure Comparison Outcome
In 2,246 high-risk unvaccinated adults with COVID-19, nirmatrelvir-ritonavir within 5 days of symptom onset reduced COVID-19-related hospitalisation or death by day 28 compared with placebo.
N
2,246
Design
Double-blind RCT
Endpoint
Hospitalisation or death at 28 days
Relevance
2
Result0.77 % vs 6.31 %; ~89 % relative reduction.
Hammond J, et al. N Engl J Med. 2022;386(15):1397-1408. 10.1056/NEJMoa2118542
Discussion & critique
Cornerstone outpatient antiviral — caveat: efficacy in vaccinated lower-risk patients and drug-drug interactions limit real-world impact.